Copyright Reports & Markets. All rights reserved.

Global CD40 Ligand Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 CD40 Ligand Market Overview

      • 1.1 Product Overview and Scope of CD40 Ligand
      • 1.2 CD40 Ligand Segment by Type
        • 1.2.1 Global CD40 Ligand Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 ISF-35
        • 1.2.3 LOAd-700
        • 1.2.4 MEDI-4920
        • 1.2.5 MegaCD40L
        • 1.2.6 Others
      • 1.3 CD40 Ligand Segment by Application
        • 1.3.1 CD40 Ligand Consumption Comparison by Application (2014-2025)
        • 1.3.2 Hepatitis B
        • 1.3.3 Bladder Cancer
        • 1.3.4 Liver Cancer
        • 1.3.5 Ovarian Cancer
        • 1.3.6 Others
      • 1.3 Global CD40 Ligand Market by Region
        • 1.3.1 Global CD40 Ligand Market Size Region
        • 1.3.2 North America Status and Prospect (2014-2025)
        • 1.3.3 Europe Status and Prospect (2014-2025)
        • 1.3.4 China Status and Prospect (2014-2025)
        • 1.3.5 Japan Status and Prospect (2014-2025)
        • 1.3.6 Southeast Asia Status and Prospect (2014-2025)
        • 1.3.7 India Status and Prospect (2014-2025)
      • 1.4 Global CD40 Ligand Market Size
        • 1.4.1 Global CD40 Ligand Revenue (2014-2025)
        • 1.4.2 Global CD40 Ligand Production (2014-2025)

      2 Global CD40 Ligand Market Competition by Manufacturers

      • 2.1 Global CD40 Ligand Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global CD40 Ligand Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global CD40 Ligand Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers CD40 Ligand Production Sites, Area Served, Product Types
      • 2.5 CD40 Ligand Market Competitive Situation and Trends
        • 2.5.1 CD40 Ligand Market Concentration Rate
        • 2.5.2 CD40 Ligand Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global CD40 Ligand Production Market Share by Regions

      • 3.1 Global CD40 Ligand Production Market Share by Regions
      • 3.2 Global CD40 Ligand Revenue Market Share by Regions (2014-2019)
      • 3.3 Global CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America CD40 Ligand Production
        • 3.4.1 North America CD40 Ligand Production Growth Rate (2014-2019)
        • 3.4.2 North America CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe CD40 Ligand Production
        • 3.5.1 Europe CD40 Ligand Production Growth Rate (2014-2019)
        • 3.5.2 Europe CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China CD40 Ligand Production (2014-2019)
        • 3.6.1 China CD40 Ligand Production Growth Rate (2014-2019)
        • 3.6.2 China CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan CD40 Ligand Production (2014-2019)
        • 3.7.1 Japan CD40 Ligand Production Growth Rate (2014-2019)
        • 3.7.2 Japan CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global CD40 Ligand Consumption by Regions

      • 4.1 Global CD40 Ligand Consumption by Regions
      • 4.2 North America CD40 Ligand Consumption (2014-2019)
      • 4.3 Europe CD40 Ligand Consumption (2014-2019)
      • 4.4 China CD40 Ligand Consumption (2014-2019)
      • 4.5 Japan CD40 Ligand Consumption (2014-2019)

      5 Global CD40 Ligand Production, Revenue, Price Trend by Type

      • 5.1 Global CD40 Ligand Production Market Share by Type (2014-2019)
      • 5.2 Global CD40 Ligand Revenue Market Share by Type (2014-2019)
      • 5.3 Global CD40 Ligand Price by Type (2014-2019)
      • 5.4 Global CD40 Ligand Production Growth by Type (2014-2019)

      6 Global CD40 Ligand Market Analysis by Applications

      • 6.1 Global CD40 Ligand Consumption Market Share by Application (2014-2019)
      • 6.2 Global CD40 Ligand Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in CD40 Ligand Business

      • 7.1 Biogen, Inc.
        • 7.1.1 Biogen, Inc. CD40 Ligand Production Sites and Area Served
        • 7.1.2 CD40 Ligand Product Introduction, Application and Specification
        • 7.1.3 Biogen, Inc. CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 Bristol-Myers Squibb Company
        • 7.2.1 Bristol-Myers Squibb Company CD40 Ligand Production Sites and Area Served
        • 7.2.2 CD40 Ligand Product Introduction, Application and Specification
        • 7.2.3 Bristol-Myers Squibb Company CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 eTheRNA Immunotherapies NV
        • 7.3.1 eTheRNA Immunotherapies NV CD40 Ligand Production Sites and Area Served
        • 7.3.2 CD40 Ligand Product Introduction, Application and Specification
        • 7.3.3 eTheRNA Immunotherapies NV CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 ImmuNext, Inc.
        • 7.4.1 ImmuNext, Inc. CD40 Ligand Production Sites and Area Served
        • 7.4.2 CD40 Ligand Product Introduction, Application and Specification
        • 7.4.3 ImmuNext, Inc. CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 Juno Therapeutics Inc.
        • 7.5.1 Juno Therapeutics Inc. CD40 Ligand Production Sites and Area Served
        • 7.5.2 CD40 Ligand Product Introduction, Application and Specification
        • 7.5.3 Juno Therapeutics Inc. CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 MedImmune, LLC
        • 7.6.1 MedImmune, LLC CD40 Ligand Production Sites and Area Served
        • 7.6.2 CD40 Ligand Product Introduction, Application and Specification
        • 7.6.3 MedImmune, LLC CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 Targovax AS
        • 7.7.1 Targovax AS CD40 Ligand Production Sites and Area Served
        • 7.7.2 CD40 Ligand Product Introduction, Application and Specification
        • 7.7.3 Targovax AS CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 XL-protein GmbH
        • 7.8.1 XL-protein GmbH CD40 Ligand Production Sites and Area Served
        • 7.8.2 CD40 Ligand Product Introduction, Application and Specification
        • 7.8.3 XL-protein GmbH CD40 Ligand Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served

      8 CD40 Ligand Manufacturing Cost Analysis

      • 8.1 CD40 Ligand Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of CD40 Ligand
      • 8.4 CD40 Ligand Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 CD40 Ligand Distributors List
      • 9.3 CD40 Ligand Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global CD40 Ligand Market Forecast

      • 11.1 Global CD40 Ligand Production, Revenue Forecast
        • 11.1.1 Global CD40 Ligand Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global CD40 Ligand Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global CD40 Ligand Price and Trend Forecast (2019-2025)
      • 11.2 Global CD40 Ligand Production Forecast by Regions (2019-2025)
        • 11.2.1 North America CD40 Ligand Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe CD40 Ligand Production, Revenue Forecast (2019-2025)
        • 11.2.3 China CD40 Ligand Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan CD40 Ligand Production, Revenue Forecast (2019-2025)
      • 11.3 Global CD40 Ligand Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America CD40 Ligand Consumption Forecast (2019-2025)
        • 11.3.2 Europe CD40 Ligand Consumption Forecast (2019-2025)
        • 11.3.3 China CD40 Ligand Consumption Forecast (2019-2025)
        • 11.3.4 Japan CD40 Ligand Consumption Forecast (2019-2025)
      • 11.4 Global CD40 Ligand Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global CD40 Ligand Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global CD40 Ligand market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on CD40 Ligand volume and value at global level, regional level and company level. From a global perspective, this report represents overall CD40 Ligand market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        Biogen, Inc.
        Bristol-Myers Squibb Company
        eTheRNA Immunotherapies NV
        ImmuNext, Inc.
        Juno Therapeutics Inc.
        MedImmune, LLC
        Targovax AS
        XL-protein GmbH

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        ISF-35
        LOAd-700
        MEDI-4920
        MegaCD40L
        Others

        Segment by Application
        Hepatitis B
        Bladder Cancer
        Liver Cancer
        Ovarian Cancer
        Others

        Buy now